Ocular Therapeutix (NASDAQ:OCUL - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They currently have a $28.00 target price on the biopharmaceutical company's stock. HC Wainwright's target price would indicate a potential upside of 365.89% from the stock's previous close.
OCUL has been the subject of a number of other reports. Chardan Capital reaffirmed a "buy" rating and issued a $23.00 price objective on shares of Ocular Therapeutix in a research note on Friday, October 2nd. Needham & Company LLC reissued a "buy" rating and set a $18.00 target price on shares of Ocular Therapeutix in a research report on Monday, October 19th. Weiss Ratings restated a "sell (d-)" rating on shares of Ocular Therapeutix in a report on Thursday, October 15th. UBS Group started coverage on shares of Ocular Therapeutix in a report on Sunday, October 11th. They issued a "buy" rating and a $14.00 price target for the company. Finally, Zacks Research raised shares of Ocular Therapeutix from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $23.83.
Read Our Latest Research Report on Ocular Therapeutix
Ocular Therapeutix Price Performance
Shares of OCUL stock opened at $6.01 on Tuesday. Ocular Therapeutix has a twelve month low of $5.94 and a twelve month high of $16.44. The company has a current ratio of 9.12, a quick ratio of 13.03 and a debt-to-equity ratio of 0.17. The stock has a fifty day simple moving average of $7.90 and a two-hundred day simple moving average of $8.89. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -4.12 and a beta of 1.22.
Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.06). The firm had revenue of $12.87 million for the quarter, compared to analysts' expectations of $14.27 million. Ocular Therapeutix had a negative net margin of 648.64% and a negative return on equity of 59.95%. The business's quarterly revenue was down 11.5% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.38) EPS. On average, analysts predict that Ocular Therapeutix will post -1.61 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, insider Jeffrey S. Heier sold 10,869 shares of the company's stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $7.05, for a total transaction of $76,626.45. Following the completion of the sale, the insider directly owned 307,457 shares in the company, valued at $2,167,571.85. This represents a 3.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Namrata Saroj sold 35,370 shares of the firm's stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $6.55, for a total value of $231,673.50. Following the sale, the insider directly owned 220,522 shares in the company, valued at approximately $1,444,419.10. The trade was a 13.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 98,090 shares of company stock worth $787,920. Insiders own 3.10% of the company's stock.
Hedge Funds Weigh In On Ocular Therapeutix
Large investors have recently added to or reduced their stakes in the company. CSM Advisors LLC grew its holdings in Ocular Therapeutix by 4.9% in the third quarter. CSM Advisors LLC now owns 199,431 shares of the biopharmaceutical company's stock worth $1,530,000 after purchasing an additional 9,237 shares during the last quarter. Cetera Investment Advisers increased its position in shares of Ocular Therapeutix by 4.6% during the third quarter. Cetera Investment Advisers now owns 822,060 shares of the biopharmaceutical company's stock worth $6,305,000 after purchasing an additional 36,328 shares in the last quarter. Jump Financial LLC lifted its holdings in shares of Ocular Therapeutix by 31.5% during the 3rd quarter. Jump Financial LLC now owns 461,411 shares of the biopharmaceutical company's stock valued at $3,539,000 after purchasing an additional 110,474 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Ocular Therapeutix by 2,047.2% during the 3rd quarter. Marshall Wace LLP now owns 2,706,184 shares of the biopharmaceutical company's stock valued at $20,756,000 after purchasing an additional 2,580,151 shares during the last quarter. Finally, Private Advisor Group LLC purchased a new stake in shares of Ocular Therapeutix during the 3rd quarter valued at $130,000. 59.21% of the stock is currently owned by institutional investors.
Ocular Therapeutix Company Profile
(
Get Free Report)
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time. Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ocular Therapeutix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocular Therapeutix wasn't on the list.
While Ocular Therapeutix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.